{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:48:55Z","timestamp":1793306935016,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00198-021-05925-3","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T12:02:58Z","timestamp":1616760178000},"page":"1999-2009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study"],"prefix":"10.1007","volume":"32","author":[{"given":"A.","family":"Tominaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Terayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"5925_CR1","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1093\/ije\/dyp276","volume":"39","author":"N Yoshimura","year":"2010","unstructured":"Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T (2010) Cohort profile: research on osteoarthritis\/osteoporosis against disability study. Int J Epidemiol 39:988\u2013995. https:\/\/doi.org\/10.1093\/ije\/dyp276","journal-title":"Int J Epidemiol"},{"key":"5925_CR2","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s00774-009-0080-8","volume":"27","author":"N Yoshimura","year":"2009","unstructured":"Yoshimura N, Muraki S, Oka H, Mabuchi A, En-Yo Y, Yoshida M, Saika A, Yoshida H, Suzuki T, Yamamoto S, Ishibashi H, Kawaguchi H, Nakamura K, Akune T (2009) Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis\/osteoporosis against disability study. J Bone Miner Metab 27:620\u2013628. https:\/\/doi.org\/10.1007\/s00774-009-0080-8","journal-title":"J Bone Miner Metab"},{"key":"5925_CR3","doi-asserted-by":"publisher","first-page":"115574","DOI":"10.1016\/j.bone.2020.115574","volume":"140","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirao M, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A, Nakaya H, Kunugiza Y, Okamura G, Etani Y, Takami K, Goshima A, Nakata K (2020) Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 140:115574. https:\/\/doi.org\/10.1016\/j.bone.2020.115574","journal-title":"Bone"},{"key":"5925_CR4","doi-asserted-by":"publisher","unstructured":"Tominaga A, Wada K, Kato Y, Nishi H, Terayama Y, Okazaki K (2020) Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-020-05639-y","DOI":"10.1007\/s00198-020-05639-y"},{"key":"5925_CR5","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1210\/en.2007-0270","volume":"148","author":"R Baron","year":"2007","unstructured":"Baron R, Rawadi G (2007) Targeting the Wnt\/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148:2635\u20132643. https:\/\/doi.org\/10.1210\/en.2007-0270","journal-title":"Endocrinology"},{"key":"5925_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"},{"key":"5925_CR7","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jbmr.14","volume":"25","author":"MS Ominsky","year":"2010","unstructured":"Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25:948\u2013959. https:\/\/doi.org\/10.1002\/jbmr.14","journal-title":"J Bone Miner Res"},{"key":"5925_CR8","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1002\/jbmr.182","volume":"25","author":"X Li","year":"2011","unstructured":"Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ (2011) Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 25:2647\u20132656. https:\/\/doi.org\/10.1002\/jbmr.182","journal-title":"J Bone Miner Res"},{"key":"5925_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/14712598.2017.1280455","volume":"17","author":"L Bandeira","year":"2017","unstructured":"Bandeira L, Lewiecki EM, Bilezikian JP (2017) Romosozumab for the treatment of osteoporosis. Expert Opin Biol Ther 17:255\u2013263. https:\/\/doi.org\/10.1080\/14712598.2017.1280455","journal-title":"Expert Opin Biol Ther"},{"key":"5925_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-019-0608-z","volume":"14","author":"A Miyauchi","year":"2019","unstructured":"Miyauchi A, Dinavahi RV, Crittenden DB et al (2019) Increased bone mineral density for 1 year of romosozumab vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos 14:59. https:\/\/doi.org\/10.1007\/s11657-019-0608-z","journal-title":"Arch Osteoporos"},{"key":"5925_CR11","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"key":"5925_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239\u2013245. https:\/\/doi.org\/10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"5925_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s002239900497","volume":"63","author":"BJ Gertz","year":"1998","unstructured":"Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S (1998) Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63:102\u2013106. https:\/\/doi.org\/10.1007\/s002239900497","journal-title":"Calcif Tissue Int"},{"key":"5925_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s1570-0232(02)00431-2","volume":"781","author":"Y Igarashi","year":"2002","unstructured":"Igarashi Y, Lee MY, Matsuzaki S et al (2002) Acid phosphatase as markers of bone metabolism. J Chromatogr B 781:345\u2013358. https:\/\/doi.org\/10.1016\/s1570-0232(02)00431-2","journal-title":"J Chromatogr B"},{"key":"5925_CR15","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.clinbiochem.2014.04.007","volume":"47","author":"E Cavalier","year":"2014","unstructured":"Cavalier E, Souberlielle JC, Grandisseur R et al (2014) Inter-method variability in bone alkaline phosphatase measurement: clinical impact on the management of dialysis patients. Clin Biochem 47:1227\u20131230. https:\/\/doi.org\/10.1016\/j.clinbiochem.2014.04.007","journal-title":"Clin Biochem"},{"key":"5925_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1185\/030079905X75096","volume":"22","author":"R Eastell","year":"2006","unstructured":"Eastell R, Krege JH, Chen P, Glass EV, Reginster JY (2006) Development of analgorism for using P1NP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22:61\u201366. https:\/\/doi.org\/10.1185\/030079905X75096","journal-title":"Curr Med Res Opin"},{"key":"5925_CR17","first-page":"2015","volume":"41","author":"I Fogelman","year":"2000","unstructured":"Fogelman I, Blake GM (2000) Different approaches to bone densitometry. J Nucl Med 41:2015\u20132025","journal-title":"J Nucl Med"},{"key":"5925_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cca.2019.08.012","volume":"498","author":"Y Nishizawa","year":"2019","unstructured":"Nishizawa Y, Miura M, Ichimura S, Inaba M, Imanishi Y, Shiraki M, Takada J, Chaki O, Hagino H, Fukunaga M, Fujiwara S, Miki T, Yoshimura N, Ohta H (2019) Executive summary of the Japan osteoporosis society guide for the use of bone turnover markers in the diagnosis and treatment of osteoporosis (2018 edition). Clin Chim Acta 498:101\u2013107. https:\/\/doi.org\/10.1016\/j.cca.2019.08.012","journal-title":"Clin Chim Acta"},{"key":"5925_CR19","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"key":"5925_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/mab.2019.0049","volume":"39","author":"G Mariscal","year":"2020","unstructured":"Mariscal G, Munez JH, Bhatia S et al (2020) Safety of romosozumab in osteoporotic men and postmenopausal women: a meta-analysis and systematic review. Monoclon Antib Immunodiagn Immunother 39:29\u201336. https:\/\/doi.org\/10.1089\/mab.2019.0049","journal-title":"Monoclon Antib Immunodiagn Immunother"},{"issue":"4","key":"5925_CR21","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1210\/jc.2015-4181","volume":"101","author":"DW Dempster","year":"2016","unstructured":"Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Janos B, Ruff VA (2016) Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study. J Clin Endocrinol Metab. 101(4):1353\u20131363. https:\/\/doi.org\/10.1210\/jc.2015-4181","journal-title":"J Clin Endocrinol Metab."},{"key":"5925_CR22","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00520-009-0704-5","volume":"17","author":"SA Polyzos","year":"2009","unstructured":"Polyzos SA, Anastasilakis AD, Terpos E (2009) Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. Support Care Canser 17:1329\u20131330","journal-title":"Support Care Canser"},{"key":"5925_CR23","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomized, open-label, phase 3 trial. Lancet 390:1585\u20131594. https:\/\/doi.org\/10.1016\/S0140-6736(17)31613-6","journal-title":"Lancet"},{"key":"5925_CR24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00198-005-2025-y","volume":"17","author":"SW Veich","year":"2006","unstructured":"Veich SW, Findlay SC, Hamer AJ et al (2006) Changes in bone mass and bone turnover following tibial shaft fracture. Osteoporos Int 17:364\u2013372. https:\/\/doi.org\/10.1007\/s00198-005-2025-y","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-05925-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-021-05925-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-05925-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:00:59Z","timestamp":1744171259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-021-05925-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5925"],"URL":"https:\/\/doi.org\/10.1007\/s00198-021-05925-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"4 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Tokyo Women\u2019s Medical University Ethics Committee, number 5596.Informed consent was obtained from all participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ayako Tominaga, Yoshiharu Kato, Hideharu Nishi, Yasushi Terayama, and Ken Okazaki declare that they have no conflicts of interest. Keiji Wada received a speaking fee from Amgen Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}